Comparative Efficacy of Combination Therapy of Ipilimumab Plus Nivolumab for Non-clear Cell Renal Cell Carcinoma.
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Carcinoma, Renal Cell
/ drug therapy
Female
Humans
Immune Checkpoint Inhibitors
/ therapeutic use
Ipilimumab
/ therapeutic use
Kidney Neoplasms
/ drug therapy
Male
Middle Aged
Molecular Targeted Therapy
Nivolumab
/ therapeutic use
Progression-Free Survival
Retrospective Studies
Survival Rate
Treatment Outcome
Non-clear cell renal cell carcinoma
immune checkpoint inhibitor
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
24
11
2021
revised:
16
12
2021
accepted:
23
12
2021
entrez:
30
1
2022
pubmed:
31
1
2022
medline:
9
2
2022
Statut:
ppublish
Résumé
The survival benefit of immune checkpoint inhibitors for non-clear cell renal cell carcinoma (nccRCC) is unclear. Our purpose was to evaluate the real-world survival benefit of ipilimumab plus nivolumab retrospectively. We retrospectively reviewed medical records of 33 patients with metastatic nccRCC who received combination therapy with ipilimumab plus nivolumab or monotherapy with a molecular targeted agent as initial systemic therapy. Progression-free survival (PFS), overall survival (OS) and objective response rate were compared between the two groups. Median PFS of each therapy was 3.5 and 4.7 months (p=0.61) and median OS was 19.6 and 10.6 months (p=0.23), respectively. Three patients treated with ipilimumab and nivolumab had a complete response, resulting in an objective response rate of 30.0%, while that for molecular targeted therapy was 4.5% (p=0.04). Ipilimumab plus nivolumab achieved statistically non-significant, but longer overall survival and significantly higher objective response rate.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
The survival benefit of immune checkpoint inhibitors for non-clear cell renal cell carcinoma (nccRCC) is unclear. Our purpose was to evaluate the real-world survival benefit of ipilimumab plus nivolumab retrospectively.
PATIENTS AND METHODS
METHODS
We retrospectively reviewed medical records of 33 patients with metastatic nccRCC who received combination therapy with ipilimumab plus nivolumab or monotherapy with a molecular targeted agent as initial systemic therapy. Progression-free survival (PFS), overall survival (OS) and objective response rate were compared between the two groups.
RESULTS
RESULTS
Median PFS of each therapy was 3.5 and 4.7 months (p=0.61) and median OS was 19.6 and 10.6 months (p=0.23), respectively. Three patients treated with ipilimumab and nivolumab had a complete response, resulting in an objective response rate of 30.0%, while that for molecular targeted therapy was 4.5% (p=0.04).
CONCLUSION
CONCLUSIONS
Ipilimumab plus nivolumab achieved statistically non-significant, but longer overall survival and significantly higher objective response rate.
Identifiants
pubmed: 35093897
pii: 42/2/973
doi: 10.21873/anticanres.15557
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Ipilimumab
0
Nivolumab
31YO63LBSN
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
973-979Informations de copyright
Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.